Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2675-2679

  Kawamoto, Teruya ^a   Akisue, Toshihiro ^a   Marui, Takashi ^a   Nakatani, Tetsuya ^a   Hitora, Toshiaki ^a   Fujita, Ikuo ^b   Kurosaka, Masahiro ^a   Yamamoto, Tetsuji ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

c kit; Malignant fibrous histiocytoma; Platelet derived growth factor receptor; STI571; Tyrosine kinase

Indexed keywords

IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMATOFIBROMA; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

CELL LINE, TUMOR; CELL PROLIFERATION; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; PIPERAZINES; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, MESSENGER;

EID: 6444228814     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Papai Z, Bodoky G, Szanto J, Poller I, Rahoty P, Eckhardt S, Lang I and Szendroi M: The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer 89: 177-180, 2000.
2. Reichardt P: High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 41: 157-167, 2002.
3. Spira AI and Ettinger DS: The use of chemotherapy in soft tissue sarcomas. Oncologist 7: 348-359, 2002.
4. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y and Takagi H: Coexpression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 6: 2291-2296, 1991.
5. Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S and Schutte J: Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 51: 261-265, 2003.
6. Yamamoto S, Kubo S, Shuto T, Yamamoto T, Hirohashi K, Tanaka H, Takemura S, Kanazawa A and Kinoshita H: Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases. J Gastroenterol 38: 896-899, 2003.
7. Chen H, Isozaki K, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y, Kitamura Y and Hirota S: Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 105: 130-135, 2003.
8. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB and Fidler IJ: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534-6544, 2003.
9. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ and Bar-Eli M. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591, 2002.
10. Yamamoto T, Akisue T, Marui T, Fujita I, Matsumoto K, Kawamoto T, Hitora T, Nakatani T, Nagira K and Kurosaka M: Immunohistochemical analysis of platelet-derived growth factor and its receptors in soft tissue malignant fibrous histiocytoma. Anticancer Res 23: 4325-4328, 2003.
11. Taniuchi K, Yamada Y, Nonomura A and Takehara K: Immunohistochemical analysis of platelet-derived growth, factor and its receptors in fibrohistiocytic tumors. J Cutan Pathol 24: 393-397, 1997.
12. Nakatani T, Marui T, Yamamoto T, Hitora T, Akisue T, Kawamoto T, Nagira K, Fujita I, Matsumoto K, Yoshiya S and Kurosaka M: Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1). Anticancer Res 23: 2329-2333, 2003.
13. Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE and Wasteson A: Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Eur J Cancer 34: 2094-2100, 1998.
14. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952, 1997.
15. Deininger MW, Goldman JM, Lydon N and Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698, 1997.
16. Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD and Zeller WJ: Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol 44: 433-438, 1999.
17. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
18. Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000.
19. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A and Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apotosis. Cancer Res 61: 5778-5783, 2001.
20. Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP and Ostman A: The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 59: 3719-3723, 1999.
21. Greco A, Roccato E, Miranda C, Cleris L, Formelli F and Pierotti MA: Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PD GFB rearrangement. Int J Cancer 92: 354-360, 2001.
22. Li J, Kleeff J, Guo J, Fischer L, Giese N, Buchler MW and Friess H: Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer 2: 32, 2003.
23. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK and Janson ET: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9: 1469-1473, 2003.
24. Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P and Picci P: C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 21: 1952-1960, 2003.
25. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G and Dominici C: c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 106: 147-152, 2003.
26. Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T and Matsumoto K: Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma. Pathol Int 57: 595-602, 2001.
27. Fang Z, Mukai H, Nomura K, Shinomiya K, Matsumoto S, Kawaguchi N, Kitagawa T and Kanda H: Establishment and characterization of a cell line from a malignant fibrous histiocytoma of bone developing in a patient with multiple fibrous dysplasia. J Cancer Res Clin Oncol 128: 45-49, 2002.
28. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and Tsubura A: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 727: 7-15, 2001.
29. Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, Delia Rocca C, Manicone A, Carani C, Spera G and Gnessi L: Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-α and -β during human testicular development and disease. J Clin Endocrinol Metab 87: 2310-2319, 2002.
30. Welker P, Grabbe J, Gibbs B, Zuberbier T and Henz BM: Nerve growth factor-b induces mast cell marker expression during in vitro culture of human umbilical cord blood cells. Immunology 99: 418-426, 2000.
31. Adler H, Frech B, Thony M, Pfister H, Peterhans E and Jungi TW: Inducible nitric oxide synthase in cattle. Differential cytokine regulation of nitric oxide synthase in bovine and murine macrophages. J Immunol 154: 4710-4718, 1995.
32. Verweij J, van Oosterom AT, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M and Nielsen OS: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006-2011, 2003.
33. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donate di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S and Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 Suppl 5: S83-87, 2002.
34. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423, 2001.
35. Vlahovic G and Crawford J: Activation of tyrosine kinases in cancer. Oncologist 8: 531-538, 2003.
36. Druker BJ: STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8 Suppl 4: S14-18, 2002.
37. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 725: 660-667, 2003.